Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

LONDON, January 16, 2014 /PRNewswire/ --

Uncommon nerve disorders - new study explains technological and commercial prospects

What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.

So see what's possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains.

Read on to explore those treatments and find what their future could be worth.

Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders

Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get a feel for technologies, regulatory outlooks, and developments (R&D). You also get 41 tables, 40 charts, and two interviews from the industry.

Knowledge to help your work and save time, helping your influence

Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases. There also see how you can save time. And find how you could benefit your authority through better understanding the present and future.

So the following sections explain what you get in that new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? What's its potential? Discover in our work overall world revenue to 2024 for orphan-drug CNS therapy.

Also in that report you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
• Huntington's disease (HD)
• Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease, motor neurone disease)
• Myasthenia gravis (MG)
• Other treatment applications.

How will those categories expand? Which classes of therapy can generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales for treating the rarer abnormalities causing neurodegeneration, autoimmune neuromuscular disorder, and other nerve disease.

You also assess top products' futures.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Predictions of leading agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for four marketed drugs:
• Xenazine (tetrabenazine)
• Rilutek (riluzole)
• Mestinon (pyridostigmine)
• Imuran (azathioprine).

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and potentials.

Our study also divides its overall prediction into geographical regions.

Healthcare in leading national markets - what outlooks for those CNS drug sales?

In developed and developing countries, opportunities for providers of orphan neurological medicines will increase from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for those specialist medicines.

Explore, too, how that neurological pharma technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.

Events and forces for developing, producing, marketing, and selling CNS orphan medicines

Our report shows you issues and events affecting that pharmaceuticals sector from 2014, including these:
• Candidates in development - R&D pipelines - for those indications
• Benefits of orphan drug designation
• Treatment needs - unmet and under-met - stimulating demand
• Regulatory incentives for developers, producers, and sellers.

And these influences:
• Drug launches expected and their implications for that industry and market
• Potential for orphan CNS products in emerging national markets
• Innovations - including drug-device combinations, neurotrophic factors to reverse disease, cellular therapy, and stimulating of neuronal growth
• Companion diagnostics and personalised medicine.

There you explore political, economic, social, and technological questions, investigating outlooks for commerce. Discover what the future holds.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Examine, then, what stimulates and restrains players in that industry, and affects results.

Companies and 2018 market value - find prospects for success

What happens next? From 2014 new and novel treatments and regulations there encourage investments, medical advances, and higher revenues.

Our report, then, predicts the world market for drugs treating those rare CNS conditions will exceed $2.5bn in 2018. There big pharma and specialty companies can gain. Explore how.

There you examine activities of many companies, including these:
• GlaxoSmithKline (GSK)
• Lundbeck
• Valeant Pharmaceuticals
• Teva Pharmaceutical Industries
• BrainStorm Cell Therapeutics.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. From this decade, patients, payers, and pharmaceutical companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.

Ways Orphan Drugs for CNS Diseases: R&D and Market 2014-2024  helps you

In particular, our investigation gives you these advantages:
• Revenues there to 2024 at world level, for 4 submarkets, and 4 top products - examine outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - assess developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

That study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the commercial possibilities.

With that data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort with our study, helping your decisions.

Predictions for that medical biotechnology - gain now by trying our report

Our new report is for everyone investigating applied neurology and medicines for CNS disorders. So find projections you need. Avoid missing out, then - please order now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1178/Orphan-Drugs-for-CNS-Diseases-R-D-and-Market-2014-2024

Companies Listed in this report:

Alexion Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA, Brazil)
Alnylam Pharmaceuticals
Apotex
Aspen Pharmacare
Avicena Group
Bayhill Therapeutics
BHR Pharma
Biogen Idec
Biokine Therapeutics
Biovail
BrainStorm Cell Therapeutics
California's Stem Cell Agency
Cambridge Laboratories
Ceregene
Chaperone Therapeutics
Committee for Orphan Medicinal Products (COMP)
Core Pharmaceuticals
Cortex Pharmaceuticals
Covis Pharmaceuticals
Cytokinetics
Edison Pharmaceuticals
Eisai
European Commission
European Medicines Agency (EMA)
European Union
Food and Drug Administration (FDA, US)
Glenmark Generics
Global Pharmaceuticals (generics division of Impax Laboratories
GlaxoSmithKline (GSK)
Huntington's Disease Society of America (HDSA)
Isis Pharmaceuticals
Lundbeck
Massachusetts General Hospital
Medtronic
Ministry of Health, Labor and Welfare (MHLW, Japan)
Mitsubishi Tanabe
National Institute for Health and Care Excellence (NICE)
National Institute for Neurological Disorders and Stroke (NINDS)
Neuralstem
Neuraltus Pharmaceuticals
NeuroNova
NeuroSearch
Novartis
NsGene
Omerus Corporation
Oryzon Genomics
Pfizer
Prana Biotechnology
Prestwick Pharmaceuticals
Prometheus Laboratories
Prosensa
Raptor Pharmaceuticals
Rare Disease UK
Roche
Roxane Pharmaceuticals
Russian Ministry of Health and Social Development (MOHSD)
Sangamo Biosciences
Sanofi
Shire
Siena Biotechnology
State Food and Drug Administration (SFDA, China)
Sun Pharmaceutical Industries
Teva Pharmaceuticals
The ALS Therapy Development Institute
University Hospital Tübingen
University of Kyoto
Valeant Pharmaceuticals
World Health Organisation (WHO)
Zydus Pharmaceuticals

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com